Status:
TERMINATED
An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This single arm observational study will assess the duration and safety of treatment with trastuzumab in routine clinical practice in participants with early or metastatic HER2-positive breast cancer....
Eligibility Criteria
Inclusion
- HER2-positive breast cancer
- Treated with trastuzumab in accordance with Summary of Product Characteristics and local protocols
- Written informed consent to data collection
Exclusion
- Any contraindication to trastuzumab
- Clinically relevant cardiovascular disorder or disease
Key Trial Info
Start Date :
April 14 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 15 2015
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT01187381
Start Date
April 14 2010
End Date
October 15 2015
Last Update
October 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cluj Clinical County Hospital; Oncology Dept
Cluj-Napoca, Romania, 400006